Therapeutic management of patients with COVID-19: a systematic review

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorTobaiqy, M.-
Autor(es): dc.creatorQashqary, M.-
Autor(es): dc.creatorAl-Dahery, S.-
Autor(es): dc.creatorMujallad, A.-
Autor(es): dc.creatorHershan, A. A.-
Autor(es): dc.creatorKamal, M. A.-
Autor(es): dc.creatorHelmi, N.-
Data de aceite: dc.date.accessioned2026-02-09T12:34:24Z-
Data de disponibilização: dc.date.available2026-02-09T12:34:24Z-
Data de envio: dc.date.issued2020-09-30-
Data de envio: dc.date.issued2020-09-30-
Data de envio: dc.date.issued2020-09-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/43255-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S2590088920300251-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1164001-
Descrição: dc.descriptionBackground Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was declared a global pandemic by the World Health Organization on 11th March 2020. The treatment guidelines for COVID-19 vary between countries, yet there is no approved treatment to date. Aim To report any evidence of therapeutics used for the management of patients with COVID-19 in clinical practice since emergence of the virus. Methods A systematic review protocol was developed based on the PRISMA statement. Articles for review were selected from Embase, Medline and Google Scholar. Readily accessible peer-reviewed, full articles in English published from 1st December 2019 to 26th March 2020 were included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral and antibacterial. There were no restrictions on the types of study eligible for inclusion. Results Four hundred and forty-nine articles were identified in the literature search; of these, 41 studies were included in this review. These were clinical trials (N=3), case reports (N=7), case series (N=10), and retrospective (N=11) and prospective (N=10) observational studies. Thirty-six studies were conducted in China (88%). Corticosteroid treatment was reported most frequently (N=25), followed by lopinavir (N=21) and oseltamivir (N=16). Conclusions This is the first systematic review to date related to medication used to treat patients with COVID-19. Only 41 studies were eligible for inclusion, most of which were conducted in China. Corticosteroid treatment was reported most frequently in the literature.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceInfection Prevention in Practice-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectHydroxychloroquine-
Palavras-chave: dc.subjectArbidol hydrochloride-
Palavras-chave: dc.subjectCorticosteroids-
Palavras-chave: dc.subjectConvalescent plasma therapy-
Título: dc.titleTherapeutic management of patients with COVID-19: a systematic review-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.